Replies to post #16807 on OncoSec Medical Inc (ONCSQ)

[salgovernale69]

If you've done any due diligence and paid any attention to ONCS over the last several weeks, you'd realize that it's almost certainly not the case here. The news has been nothing but good in terms of the science and the addition of high profile doctors who would never affiliate their good names with a company that they thought was "playing octopus."

There was a dilution, but as far as we know it was done to strengthen the company's position for partnership negotiations and to help fund the growing R&D Department. This dilution was also a direct offering to "highly respected" biotech investors, per the CEO. That dilution has led to this short-term price hit but once the dust settles and final Phase 2a data is released followed by Phase 2b trial plans, I expect that those buying at these prices will be handsomely rewarded.

[Waitforit53]

"And if something is going on behind the curtains, it's not good news"

Let me just say this about that.ONCS already has CE approval in Europe China and Australia. They've halted NeoPulse trials due to a change in their business plan regarding immuno pulse, mechanism of change, cancers greatest unmet need, and now new drug development. ONCS pipeline has now become complex due to the fact that they haven't thoroughly understood the surprises that of come with IL – 12, meaning how they are getting a systemic response – how they are converting a nonresponder environment into a responder environment and being able to describe what's happening at the molecular level. They're just figuring this out right now. And that's why I think big Pharma isn't just jumping on because nobody really truly understands what's happening at the molecular level hence the slower progress with the FDA and trials.

I also think what what is coming to light with Oncosec is so dramatically going to impact cancer research and treatment that they have gone behind closed doors regarding the science, regarding negotiations and FDA is to not screw themselves by violating S EEC regulations regarding insider information, and not covering up bad news. Just think about it, everybody understands were on the verge of cancer breakthrough in dramatically increase the volume of cancer patients that will respond to treatment and Oncosec just so happened to find itself right in the thick of it with electroporation and IL 12. Big Pharma is scrambling with multiple trials going in multiple directions unsure of which will truly yield the golden egg because even they don't know. And oncosec is holding a good portion of that golden egg by turning up to 90% of nonresponders to various cancer treatments into responders – that completely changes the face of the cancer population and the marketshare from a five billion-dollar industry to a 35 billion-dollar industry. So don't go thinking "no good news" or that there's nothing at stake here – this is the biggest development in cancer history that were looking at right now with oncosec as a combination or mono therapy treatment.

They are retooling everything, staff, electroporation applicators, destinations of treatment within the body, outcome objectives, a test that differentiates low till environments that require a combination treatment from high till environments that can be treated with a monotherapy. We are just going to have to wait and let this new business plan and it's process unfold before our eyes. There's a lot of thought and energy going in to projections from projections of daily PPS movement, to FTA decisions, to potential results regarding the greatest unmet need, to partnering or buyout, or what the new drug development program is going to bring about.

Anyway you look at it you couldn't be any further from the truth about this being about hiding bad news! That is the most fear-based, shortsighted and immature understanding of what is happening here--"so hold on loosely, but don't let go, if you cling too tightly, you're going to lose control!" Waitforit!